A controlled study of pregabalin combined with escitalopram in patients with major depressive disorder

Corresponding author: Yin Junbo, qdyjb9131@163.com

DOI: 10.12201/bmr.202501.00017

•  

  Abstract: Abstract: To explore the clinical efficacy and safety of escitalopram combined with pregabalin in patients with major depressive disorder. Methods: Sixty patients with recurrent depression were selected and divided into an experimental group (pregabalin combined with escitalopram, n = 30) and a control group (escitalopram, n = 30). The treatment course was 6 weeks. Before treatment and at the 2nd, 4th, and 6th weeks of treatment,Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA), and Treatment Emergent Symptom Scale (TESS) were used to evaluate efficacy and safety. Results: Before enrollment, there was no statistically significant difference in the scores of HAMD-17 and HAMA between the two groups (t = 0.615, P > 0.05).The scores after 2, 4, and 6 weeks of treatment were all lower than those before treatment. At the end of the 2nd week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 4th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 6th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Pregabalin combined with escitalopram can relieve anxiety symptoms and have antidepressant efficacy more quickly and effectively in patients with MDD.

  Key words: Pregabalin; Escitalopram; Major Depressive Disorder; Generalised anxiety disorder

  Submit time: 6 January 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• CHEN Manman, TENG Yuxin, ZENG Botao. Study on self-injurious and suicidal behavior, non-enzymatic antioxidants and thyroid hormones in adolescents with depressive disorder. 2024. doi: 10.12201/bmr.202412.00022

  YU Feng, ZOU Xiao-jie, XU Zhen. The relationship between hyperactivity behavior in children with attention deficit hyperactivity disorder and serum levels of thyroid-stimulating hormone. 2024. doi: 10.12201/bmr.202411.00024

  YANG Qing. Clinical Observation of Qinggan Ningxin Zhidong Prescription in the Treatment of Attention Deficit Hyperactivity Disorder with Heart-Liver Fire Blazing Syndrome. 2024. doi: 10.12201/bmr.202412.00051

  丁喜凤, LIU Zhaopeng, ZHONG Yingqi, ZHENG Jinghui. Research Progress on Traditional Chinese Medicine in Treating Anxiety or Depression After Percutaneous Coronary Intervention (PCI) for Coronary Heart Disease. 2025. doi: 10.12201/bmr.202503.00078

  fengxiaojuan, liyang, yanzihui, fanzhiliang. A Study on the Psychological Health Status of Migraine Patients. 2024. doi: 10.12201/bmr.202408.00034

  ma guang fan, chen xiao zhen, zhou sen. Effect of esketamine on early postoperative mental state in patients with breast cancer. 2024. doi: 10.12201/bmr.202412.00054

  Wang Yeliu, Zhou Shuping. Clinical efficacy and safety of Esomeprazole combined with Biling Weitong granules in the treatment of EPS. 2025. doi: 10.12201/bmr.202501.00052

  DU Ben-feng, GENG Rui, MU Yue-xuan, HAO Xin, WANG Jing-wen. Childhood Family Dysfunction and Depression in the Elderly: Impact Contribution, Cumulative Effect and Influence mechanism. 2022. doi: 10.12201/bmr.202111.00022

  HU Linlin, ZHANG Yonghua. Study on early intervention of insomnia in depression treated by TCM syndrome differentiation. 2024. doi: 10.12201/bmr.202408.00051

  jiangyonghong. Research applications of blood markers in the diagnosis of insomnia disorders. 2025. doi: 10.12201/bmr.202502.00060

• ID	Submit time	Number	Download
  1	2024-12-07	bmr.202501.00017V1	Download

• Public  Anonymous  To author only Submit Comments